Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
In the latest session, AbCellera Biologics Inc (NASDAQ: ABCL) closed at $2.82 down -5.69% from its previous closing price of $2.99. In other words, the price has decreased by -$5.69 from its previous closing price. On the day, 5.55 million shares were traded.
Ratios:
For a deeper understanding of AbCellera Biologics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.34 and its Current Ratio is at 9.34. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On February 22, 2024, The Benchmark Company Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $9.
On December 05, 2023, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $6.KeyBanc Capital Markets initiated its Overweight rating on December 05, 2023, with a $6 target price.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 25.27 while its Price-to-Book (P/B) ratio in mrq is 0.77.
Stock Price History:
Over the past 52 weeks, ABCL has reached a high of $5.26, while it has fallen to a 52-week low of $2.34. The 50-Day Moving Average of the stock is -8.33%, while the 200-Day Moving Average is calculated to be -5.47%.
Shares Statistics:
A total of 295.16M shares are outstanding, with a floating share count of 221.93M. Insiders hold about 24.86% of the company’s shares, while institutions hold 37.40% stake in the company.
